High Uptake of Respiratory Syncitial Virus Prevention for Neonates in a Military Treatment Facility.
Where this comes from
- Record sourced from PubMed, PMID 38876155.
- Also identified by DOI 10.1016/j.jpeds.2024.114144.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We investigated the uptake of nirsevimab for infants and the bivalent respiratory syncytial virus prefusion F (RSVPreF) vaccine for pregnant persons as measures for RSV prevention during an infant's birth hospitalization in a military treatment facility. We found >85% uptake between October 2023 to February 2024. These data may aid health systems plan for future RSV seasons.
Medical subject headings
- Respiratory Syncytial Virus Infections